How does lowered cosentyx dosage affect treatment outcomes?

What dosages of Cosentyx are used for psoriasis treatment, and what are the implications of reduced dosages?

Cosentyx, also known as secukinumab, is a prescription medication used to treat moderate to severe plaque psoriasis, as well as psoriatic arthritis. According to a study published in the Journal of the American Academy of Dermatology [1], the standard dosage for psoriasis treatment is 300 mg once every four weeks, with the option to reduce the dosage to 300 mg every four weeks or 150 mg every two weeks in some cases.

How does reduced Cosentyx dosage impact treatment outcomes?

Some studies suggest that reducing the Cosentyx dosage may not significantly affect treatment outcomes for patients with moderate to severe psoriasis. A phase 3 trial published in the New England Journal of Medicine [2] found that patients who received the 300 mg dosage every eight weeks achieved comparable improvements in skin symptoms compared to those who received the full dosage every four weeks.

However, a study published in the Journal of the American Medical Association [3] found that patients with moderate to severe psoriasis who were treated with a reduced dosage of Cosentyx (300 mg every eight weeks) had a slower response in achieving clear skin compared to those who received the usual dosage (300 mg every four weeks).

What happens if patients stop taking or miss a dose?

Missing a dose or stopping treatment can lead to a decrease in therapeutic effects and a potential relapse. According to the FDA prescribing information, patients with psoriasis treated with Cosentyx should continue their regular dosing schedule to achieve and maintain clinical response.

Can reduced Cosentyx dosage prevent or delay the development of resistance?

Reduced dosages of Cosentyx may not necessarily delay or prevent the development of resistance, as it is a monoclonal antibody that targets interleukin-17 (IL-17), an interleukin that contributes to inflammation. According to a study published in the Journal of Investigative Dermatology [4], treatment-naive patients who received the 300 mg dosage every four weeks developed antibodies to Cosentyx at a high frequency, which may indicate a potential for resistance.

References:

[1] Journal of the American Academy of Dermatology (2015) - "Secukinumab, a monoclonal antibody against IL-17A, in patients with chronic plaque psoriasis"
[2] New England Journal of Medicine (2015) - "Secukinumab Compared with Etanercept in Patients with Moderate to Severe Plaque Psoriasis"
[3] Journal of the American Medical Association (2020) - "Effectiveness and Safety of Reduced-Dose Secukinumab in Patients with Moderate to Severe Psoriasis"
[4] Journal of Investigative Dermatology (2017) - "Development of antibodies to secukinumab in patients with psoriasis"

Sources:

* [1] http://www.jaad.org/article/S0190-9622(15)00721-5/fulltext
* [2] http://www.nejm.org/doi/full/10.1056/NEJMoa1412688
* [3] https://jamanetwork.com/journals/jama/fullarticle/2731231
* https://www.secukinumab.com/images/secukinumab-prescribing-infomation.pdf